TCRX - TScan Therapeutics, Inc. Common Stock

TScan Therapeutics, Inc. (TCRX)

NGM · Common · CUSIP 89854M101

Last Price•••.••

Current Yield•.••%

Yield to Call•.••%

Yield to Worst•.••%

Free registration unlocks the quote, yield calculations, price chart and full fundamentals for TCRX and every other security on QuantumOnline.

Overview Financials 🔒 Earnings 🔒 Dividends 🔒 Analysts 🔒 Ownership 🔒 ESG 🔒 Technicals 🔒

🔒

Price chart and 15 days of daily prices

Candlestick chart with moving averages, Bollinger bands and MACD. Register free to view.

Security Profile

Security Type: Common Stock
CUSIP: 89854M101
Market Cap: Small Cap
IPO: 7/16/2021 · $15.00/share

Links: Home Page Investor Relations News

Business: TScan Therapeutics, Inc. is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer.

Company Contact

CEO: Gavin MacBeath
CFO: Jason Amello
Headquarters: 830 Winter Street, Waltham, MA 02451
Phone: 857-339-9500
Investor Relations: Heather Savelle · 857-399-9840 · hsavelle@tscan.com
Email Form: Contact Form »
SEC EDGAR Filings: View filings »